PEDIATRICS Vol. 93 No. 6 June 1994, pp. 907-912
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gadomski, A. M.
Right arrow Articles by Permutt, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gadomski, A. M.
Right arrow Articles by Permutt, T.

Efficacy of Albuterol in the Management of Bronchiolitis

Anne M. Gadomski MD, MPH1, Richard Lichenstein MD1, Lisa Horton MD1, James King MD1, Virginia Keane MD1, and Thomas Permutt PhD2

1 Division of General Pediatrics, University of Maryland, Baltimore, MD
2 Department of Epidemiology and Preventive Medicine, University of Maryland, Baltimore, MD

Objective. To examine the efficacy of albuterol (0.15 mg/kg per dose) in the management of bronchiolitis.

Design. Randomized, double-blind, placebo-controlled outpatient clinical trial utilizing four study groups: nebulized albuterol, nebulized saline, oral albuterol, and oral placebo.

Setting. Pediatric emergency department and outpatient clinic at University of Maryland in Baltimore.

Patients. Eighty-eight infants (median age 5.5 months) being treated for their first episode of wheezing were randomly assigned to nebulized albuterol (n = 22), nebulized saline (n = 23), oral albuterol (n = 19), oral placebo (n = 24).

Interventions. The nebulized groups received two nebulizations 30 minutes apart, whereas the oral groups received one oral dose.

Main outcome measures. Respiratory and heart rates, clinical score, oxygen saturation (Spo2), and the infant's state, ie, asleep, awake, or feeding, were recorded at baseline and at 30 and 60 minutes after treatment

Results. Randomization produced equivalent groups in terms of demographics and baseline measures. There were no statistically significant differences in any outcomes among the four treatments, except for oral albuterol, which produced an increase in heart rate (15 beats per minute, P = .005). No differences in the need for additional treatment or hospitalization were observed. Change in the state of the infant during the trial had significant effects on respiratory rate and clinical score.

Conclusions. Albuterol is as effective as oral placebo in the management of bronchiolitis. Past studies supporting the use of albuterol did not control for effects of change in state of the infant and did not use a truly inactive placebo group. This study underscores the importance of these design components in measuring the efficacy of albuterol in infants.

Submitted on August 30, 1993
Accepted on October 27, 1993




This article has been cited by other articles:


Home page
 PediatricsHome page
Subcommittee on Diagnosis and Management of Bronch
Diagnosis and Management of Bronchiolitis
Pediatrics, October 1, 2006; 118(4): 1774 - 1793.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
V. J. King, M. Viswanathan, W. C. Bordley, A. M. Jackman, S. F. Sutton, K. N. Lohr, and T. S. Carey
Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review
Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 127 - 137.
[Abstract] [Full Text] [PDF]

Home page
 AAP Grand RoundsHome page
R. I. Paul
Oral Albuterol Is of No Benefit for Infants with Bronchiolitis
AAP Grand Rounds, August 1, 2003; 10(2): 15 - 15.
[Full Text] [PDF]

Home page
 PediatricsHome page
M. D. Mallory, D. K. Shay, J. Garrett, and W. C. Bordley
Bronchiolitis Management Preferences and the Influence of Pulse Oximetry and Respiratory Rate on the Decision to Admit
Pediatrics, January 1, 2003; 111(1): e45 - 51.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
U. R. Kotagal, J. M. Robbins, N. M. Kini, P. J. Schoettker, H. D. Atherton, and M. S. Kirschbaum
Impact of a Bronchiolitis Guideline* : A Multisite Demonstration Project
Chest, June 1, 2002; 121(6): 1789 - 1797.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
I. Amirav, I. Balanov, M. Gorenberg, A. S. Luder, M. T. Newhouse, and D. Groshar
{beta}-Agonist Aerosol Distribution in Respiratory Syncytial Virus Bronchiolitis in Infants
J. Nucl. Med., April 1, 2002; 43(4): 487 - 491.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Z. Nasr, P. J. Strouse, E. Soskolne, N. J. Maxvold, K. A. Garver, B. K. Rubin, and F. W. Moler
Efficacy of Recombinant Human Deoxyribonuclease I in the Hospital Management of Respiratory Syncytial Virus Bronchiolitis
Chest, July 1, 2001; 120(1): 203 - 208.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
P. H. Perlstein, U. R. Kotagal, C. Bolling, R. Steele, P. J. Schoettker, H. D. Atherton, and M. K. Farrell
Evaluation of an Evidence-based Guideline for Bronchiolitis
Pediatrics, December 1, 1999; 104(6): 1334 - 1341.
[Abstract] [Full Text]

Home page
 PediatricsHome page
J. V. Dobson, S. M. Stephens-Groff, S. R. McMahon, M. M. Stemmler, S. L. Brallier, and C. Bay
The Use of Albuterol in Hospitalized Infants With Bronchiolitis
Pediatrics, March 1, 1998; 101(3): 361 - 368.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. Flores and R. I. Horwitz
Efficacy of beta 2-Agonists in Bronchiolitis: A Reappraisal and Meta-analysis
Pediatrics, August 1, 1997; 100(2): 233 - 239.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
BRONCHODILATORS FOR BRONCHIOLITIS: THE CONTROVERSY CONTINUES
Journal Watch (General), June 21, 1994; 1994(621): 4 - 4.
[Full Text]